Mfg Item # 33225

A Rapid Immunoassay for the Simultaneous Direct Detection and Differential Diagnosis of SARS-CoV-2, Influenza Type A and Type B Antigen from anterior nasal and nasopharyngeal swab specimens

• COVID-19 - Anterior nasal swab specimen − Sensitivity 93.8 %, Specificity 100% - Nasopharyngeal − Sensitivity 93.1 %, Specificity 100%

• Flu A - Sensitivity 91.4%, Specificity 95.7%

• Flu B - Sensitivity 87.6%, Specificity 95.9%

• FDA Emergency Use Authorization (EUA)

• Visually read in 15 minutes

• Flocked nasopharyngeal swab for superior specimen collection and patient comfort